Core Insights - Senti Biosciences, Inc. has received an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) for achieving clinical study enrollment milestones, bringing the total received from an $8 million grant to $7.4 million [1] - The company is developing SENTI-202, a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][3] - Preliminary results from the ongoing Phase 1 trial of SENTI-202 indicate it is well-tolerated, with no dose-limiting toxicities reported and a recommended Phase 2 dose identified as 1.5 x 10^9 CAR NK cells [4] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [5] - The company's pipeline includes cell therapies engineered with Gene Circuits to address challenging liquid and solid tumor indications, demonstrating preclinical efficacy in both NK and T cells [5] Clinical Development - SENTI-202 is currently in a Phase 1 clinical trial (NCT06325748) and has shown promising preliminary results, with two out of three patients in the recommended Phase 2 dose cohort achieving a composite Complete Remission (cCR) [4] - The trial data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 supports the Logic Gate mechanism of action, with four out of four cCR patients being Measurable Residual Disease Negative (MRD-) [4]

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Senti announced in a press release issued on April 28, 2025, that "enrollmen ...

Senti Biosciences (SNTI) 2025 Conference May 08, 2025 01:00 PM ET Speaker0 Are you ready to kick it off? Yeah. Whenever you guys wanna do. Speaker1 Okay. Welcome back to the Citizens Life Science Conference. My name is Silvan Turca, and I'm a senior analyst covering precision medicines. And now it's my pleasure to introduce Sandi Biosciences. Presenting will be Tim Liu, CEO and cofounder, and Jay Cross, CFO. Thank you so much for coming and joining us today. Speaker0 Well, thanks a lot, Silvan. Appreciate t ...

Core Insights - Senti Biosciences, Inc. is advancing its lead asset, SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy targeting hematologic malignancies like AML and MDS [2][3] - The company has reported positive preliminary results from a Phase 1 clinical trial, indicating SENTI-202 is well-tolerated with no dose-limiting toxicities [4] - The mechanism of action for SENTI-202 involves a novel gene circuit that selectively kills leukemia cells while sparing healthy hematopoietic stem cells [3][8] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][6] - The company's pipeline includes engineered cell therapies targeting both liquid and solid tumors, leveraging synthetic biology for enhanced precision and control [6] Clinical Trial Details - SENTI-202 is currently in a Phase 1 trial enrolling adult patients with relapsed/refractory CD33 and/or FLT3-expressing hematologic malignancies [3] - The preliminary recommended Phase 2 dose (RP2D) for SENTI-202 was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles following lymphodepleting chemotherapy [4] - In the preliminary RP2D cohort, 2 of 3 patients achieved a composite Complete Remission (cCR), and 5 of 7 evaluable patients achieved an overall response rate (ORR) [4] Mechanism of Action - SENTI-202 utilizes a Logic Gated gene circuit to activate CAR targeting CD33 and/or FLT3, which are expressed in approximately 95% of AML patients [8] - The therapy protects healthy hematopoietic stem and progenitor cells (HSC/HSPCs) from off-tumor effects through an inhibitory CAR targeting Endomucin (EMCN) [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from ___to___ Commission File Number 001-40440 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Core Insights - Senti Biosciences, Inc. presented positive Phase 1 data for its lead program SENTI-202 at the AACR Annual Meeting, indicating potential as a treatment for Acute Myeloid Leukemia (AML) with 4 out of 7 patients achieving composite Complete Remission (cCR) [1][3][4] - The company reported financial results for Q1 2025, showing a net loss of $14.1 million, with cash and cash equivalents of approximately $33.8 million as of March 31, 2025 [9][14] Clinical Data Highlights - SENTI-202 was well tolerated with no dose-limiting toxicities, and the preliminary recommended Phase 2 dose (RP2D) was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles [4] - All 4 patients who achieved cCR were measurable residual disease (MRD) negative, and responses have been maintained for follow-ups ranging from 4+ to 8+ months [1][4] - The ongoing enrollment in the Phase 1 study aims to confirm the RP2D and expand into disease-specific cohorts [1][3] Corporate Developments - The company is advancing its Logic-Gated cell therapy approach, which may have applications in both liquid and solid tumors, providing multiple pipeline expansion opportunities [1][2] - Senti Bio has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and increase market visibility [5] Financial Overview - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024, primarily due to higher external services costs [9][14] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024 [9][14] - The total operating expenses for the quarter were $16.4 million, slightly up from $16.3 million in the same period last year [9][14]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A due to observed dose limiting toxicities [2] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a decline of 27.2%, closing at $3.64 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3] - The firm has a track record of recovering significant damages for class members, highlighting its expertise in handling such cases [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]

Core Insights - Senti Biosciences, Inc. presented positive preliminary data from the Phase 1 clinical trial of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3][5] - SENTI-202 is designed as a first-in-class off-the-shelf therapy that selectively targets CD33 and/or FLT3 antigens while sparing healthy cells, potentially widening the therapeutic window [5][6] - The company is currently enrolling adult patients with R/R CD33 and/or FLT3-expressing hematologic malignancies in the ongoing Phase 1 clinical trial [5] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][8] - The company's pipeline includes engineered cell therapies targeting challenging liquid and solid tumor indications, leveraging synthetic biology for enhanced precision and control [8] Industry Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [7] - Current treatment options for R/R AML are limited, with median overall survival typically around five months [7]

Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]